Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer

Company Anticipates IND Filing In 2022-2023

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Senti Bio raises $105m in Series B round to develop chimeric antigen receptor natural killer cell therapies. • Source: Shutterstock

Bayer AG’s venture capital arm has leapt into another cell and gene therapy financing deal, ushering in the new year with a continuation of a string of investments in the space by the VC division and the company itself that has been going at a fast clip during the past year. Meanwhile, Senti Biosciences, the start-up it is investing in, plans to use the funding to support preclinical development of its next-generation natural killer cell-based chimeric antigen receptor therapy (CAR-NK) therapies.

Leaps by Bayer and Senti Biosciences announced 6 January that the former had led a $105m series B round in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer

The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.